AAP
MRTX

Ardsley Advisory Partners’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Ardsley Advisory Partners’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,000
Closed -$258K – 174
2019
Q4 		$258K Buy
+2,000
New +$193K 0.04% 122

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ardsley Advisory Partners's MRTX Position: Q1 2020 in Review

Ardsley Advisory Partners sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2020, closing a stake of 2,000 shares — an estimated $258K sold.

Ardsley Advisory Partners first reported a position in MRTX in Q4 2019 and held it in 1 quarter. The position peaked at $258K in Q4 2019. 173 funds tracked by Wall St. Rank hold MRTX as of Q1 2020.

  • Ardsley Advisory Partners reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Ardsley Advisory Partners sold 2,000 Mirati Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $258K.
  • Ardsley Advisory Partners first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Ardsley Advisory Partners's Mirati Therapeutics, Inc. Common Stock position peaked at $258K in Q4 2019.
  • 173 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Ardsley Advisory Partners's 13F filing for Q1 2020, filed 15 May 2020.